PPP1CB and metabolic dysfunction-associated steatohepatitis: Based on MD simulation analysis, the compound XLIX was predicted to disrupt the interaction of WDR6 with PPP1CB through competitive binding and was effective in the amelioration of the phenotypes of NASH.